Covered recipient · General Payments record
AMOL RAJEEV H RAO
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$3,477.39
162 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,252.61 | 159 |
| Education | $124.78 | 2 |
| Consulting Fee | $100.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AMOL RAJEEV H RAO
NPI 1689871154 · CMS profile ID 76709
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
FOUNTAIN VALLEY, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AMOL RAJEEV H RAO, NPI 1689871154, CMS profile ID 76709. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). AMOL RAJEEV H RAO, NPI 1689871154, CMS profile ID 76709. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- AMOL RAJEEV H RAO, NPI 1689871154, CMS profile ID 76709, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
162 matching records · $3,477.39 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 162.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.02 | 08/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659764901 | CMS |
| PFIZER INC. | $10.10 | 08/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673297567 | CMS |
| CSL Behring | $19.55 | 08/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683842545 | CMS |
| PFIZER INC. | $13.57 | 08/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673738973 | CMS |
| Astellas Pharma US Inc | $23.04 | 08/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655737109 | CMS |
| TESARO, Inc. | $36.08 | 08/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675567559 | CMS |
| Merck Sharp & Dohme Corporation | $15.15 | 08/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695690195 | CMS |
| COMSORT, Inc | $100.00 | 08/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695806019 | CMS |
| PFIZER INC. | $13.66 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673774613 | CMS |
| Merck Sharp & Dohme Corporation | $19.08 | 07/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695677947 | CMS |
| Genentech USA, Inc. | $20.86 | 07/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681355841 | CMS |
| TESARO, Inc. | $27.51 | 07/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675567557 | CMS |
| Novartis Pharmaceuticals Corporation | $39.30 | 07/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659764893 | CMS |
| Janssen Pharmaceuticals, Inc | $15.21 | 07/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659224915 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $23.14 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 665708655 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3.85 | 07/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651371957 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.55 | 07/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651371959 | CMS |
| Merck Sharp & Dohme Corporation | $19.71 | 07/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695662541 | CMS |
| Merck Sharp & Dohme Corporation | $15.71 | 07/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695664077 | CMS |
| Puma Biotechnology, Inc. | $21.82 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706024867 | CMS |
| Foundation Medicine, Inc. | $24.82 | 07/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675551087 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.16 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651371947 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.31 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651371949 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.23 | 07/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697398564 | CMS |
| Octapharma USA, Inc. | $20.49 | 07/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 692225589 | CMS |
| Astellas Pharma US Inc | $18.59 | 07/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655737107 | CMS |
| Novartis Pharmaceuticals Corporation | $18.51 | 06/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659764865 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $15.33 | 06/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628421631 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.12 | 06/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697395279 | CMS |
| Clovis Oncology, Inc. | $24.68 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688688895 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.23 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673461549 | CMS |
| Clovis Oncology, Inc. | $13.53 | 06/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688689149 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.18 | 06/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651371943 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.04 | 06/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651371945 | CMS |
| PFIZER INC. | $21.34 | 06/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673635839 | CMS |
| TerSera Therapeutics LLC | $28.06 | 06/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699772489 | CMS |
| Incyte Corporation | $23.19 | 06/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666248657 | CMS |
| Incyte Corporation | $99.95 | 06/14/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666248661 | CMS |
| TerSera Therapeutics LLC | $28.06 | 06/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699772487 | CMS |
| AbbVie, Inc. | $20.00 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647728029 | CMS |
| Taiho Oncology, Inc. | $13.25 | 06/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679423817 | CMS |
| Amgen Inc. | $21.54 | 06/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662170359 | CMS |
| TESARO, Inc. | $17.60 | 05/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675567555 | CMS |
| Exelixis Inc. | $29.17 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686550261 | CMS |
| Celgene Corporation | $24.41 | 05/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673007881 | CMS |
| Merck Sharp & Dohme Corporation | $18.43 | 05/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695542145 | CMS |
| Novartis Pharmaceuticals Corporation | $12.53 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659764883 | CMS |
| Genentech USA, Inc. | $19.96 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681273119 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.71 | 05/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685503957 | CMS |
| EISAI INC. | $14.57 | 05/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697008909 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,193,955.59 | 65 |
| PY2024 | Principal investigator | $556,715.08 | 31 |
| PY2023 | Recipient | $16.15 | 1 |
| PY2023 | Principal investigator | $338,821.77 | 31 |
| PY2022 | Recipient | $1,298.00 | 1 |
| PY2022 | Principal investigator | $242,404.24 | 27 |
| PY2021 | Principal investigator | $87,262.23 | 9 |
| PY2020 | Principal investigator | $57,796.20 | 3 |
| PY2019 | Principal investigator | $10,781.31 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
65 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $34,852.28 | 12/31/2025 | Non-covered Recipient Entity MemorialCare Orange Coast Medical Center | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received | No dispute reported | 06/30/2026 | 1232923800 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $13,157.52 | 12/29/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753718 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $90.00 | 12/22/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES DBA MEMORIALCARE | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176657716 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $2,534.32 | 12/15/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753720 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $58,370.74 | 12/03/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with BRCA1,BRCA2,or PALB2 mutations and hormone receptor positive, HER2 negative IHC 0,1+,2+ISH non-amplified advanced breast cancer evoPAR breast01 | No dispute reported | 06/30/2026 | 1185544641 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $9,808.75 | 12/01/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753682 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,247.86 | 11/14/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753716 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $106.40 | 10/31/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753726 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $750.00 | 10/31/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753728 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,573.06 | 10/30/2025 | Non-covered Recipient Entity Biomedical Research Alliance of New York LLC | DS8201-A-U305 | No dispute reported | 06/30/2026 | 1244555166 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,002.00 | 10/24/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185544643 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $54,800.22 | 10/22/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185544657 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $11,521.29 | 10/15/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753714 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $370.00 | 10/02/2025 | Non-covered Recipient Entity Orange Coast Memorial Medical Center | DS8201-793 | No dispute reported | 06/30/2026 | 1223375617 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $945.00 | 10/02/2025 | Non-covered Recipient Entity Orange Coast Memorial Medical Center | DS8201-793 | No dispute reported | 06/30/2026 | 1223375619 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $23,000.00 | 09/29/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753722 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $18,706.45 | 09/29/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | ALI-1201 | No dispute reported | 06/30/2026 | 1251753724 |
| Principal investigator 1 | Exelixis Inc. | $75.00 | 09/17/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381658 |
| Principal investigator 1 | Exelixis Inc. | $75.00 | 09/17/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381660 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $2,000.00 | 09/10/2025 | Non-covered Recipient Entity Memorialcare Health System | A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio | No dispute reported | 06/30/2026 | 1236530935 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 09/09/2025 | Non-covered Recipient Entity Memorial Health Services | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228751049 |
| Principal investigator 1 | Exelixis Inc. | $1,000.00 | 08/07/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381662 |
| Principal investigator 1 | Exelixis Inc. | $3,200.00 | 08/07/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381664 |
| Principal investigator 1 | Exelixis Inc. | $1,200.00 | 08/07/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381666 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $488,536.92 | 08/06/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185544649 |
| Principal investigator 1 | Eli Lilly and Company | $3,765.00 | 08/01/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (BRUIN CLL-321) | No dispute reported | 06/30/2026 | 1187885720 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,000.00 | 07/29/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185544639 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $32,759.65 | 07/29/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185544655 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,502.00 | 07/02/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185544647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $325.56 | 06/24/2025 | Non-covered Recipient Entity MemorialCare Todd Cancer Institute | DS8201-A-U305 | No dispute reported | 06/30/2026 | 1223372184 |
| Principal investigator 1 | Exelixis Inc. | $550.00 | 06/04/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381634 |
| Principal investigator 1 | Genentech, Inc. | $10.00 | 06/04/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211623539 |
| Principal investigator 1 | Exelixis Inc. | $5,357.30 | 05/28/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381648 |
| Principal investigator 1 | Exelixis Inc. | $4,160.00 | 05/28/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381656 |
| Principal investigator 1 | Genentech, Inc. | $3,450.00 | 05/27/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211623542 |
| Principal investigator 1 | PFIZER INC. | $624.38 | 05/23/2025 | Non-covered Recipient Entity Memorial Health Services | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228764372 |
| Principal investigator 1 | Exelixis Inc. | $3,491.80 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381632 |
| Principal investigator 1 | Exelixis Inc. | $429.65 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381636 |
| Principal investigator 1 | Exelixis Inc. | $1,050.40 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381640 |
| Principal investigator 1 | Exelixis Inc. | $2,623.40 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381642 |
| Principal investigator 1 | Exelixis Inc. | $2,493.40 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381644 |
| Principal investigator 1 | Exelixis Inc. | $2,532.40 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381650 |
| Principal investigator 1 | Exelixis Inc. | $2,730.00 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381652 |
| Principal investigator 1 | Exelixis Inc. | $2,532.40 | 05/08/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381654 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $41,121.36 | 05/07/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185544635 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 05/06/2025 | Non-covered Recipient Entity Long Beach Memorial Medical Center | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | No dispute reported | 06/30/2026 | 1211621228 |
| Principal investigator 1 | PFIZER INC. | $8,949.25 | 05/01/2025 | Non-covered Recipient Entity Memorial Health Services | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228764861 |
| Principal investigator 1 | Exelixis Inc. | $32.50 | 04/11/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381638 |
| Principal investigator 1 | Exelixis Inc. | $550.00 | 04/11/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381646 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,160.50 | 03/31/2025 | Non-covered Recipient Entity MemorialCare Todd Cancer Institute | DS8201-A-U305 | No dispute reported | 06/30/2026 | 1223372182 |
| Principal investigator 1 | AstraZeneca UK Limited | $9,783.34 | 03/25/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185544651 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,231.12 | 03/19/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | No dispute reported | 06/30/2026 | 1185544645 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $31,668.03 | 03/19/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185544653 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $59,587.28 | 02/28/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III | No dispute reported | 06/30/2026 | 1185544637 |
| Principal investigator 1 | Exelixis Inc. | $2,532.40 | 02/19/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381622 |
| Principal investigator 1 | Exelixis Inc. | $2,623.40 | 02/19/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381624 |
| Principal investigator 1 | Exelixis Inc. | $3,491.80 | 02/19/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381626 |
| Principal investigator 1 | Exelixis Inc. | $1,050.40 | 02/19/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381628 |
| Principal investigator 1 | Exelixis Inc. | $2,493.40 | 02/19/2025 | Non-covered Recipient Entity Memorial Health Services | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1222381630 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 02/14/2025 | Non-covered Recipient Entity Memorial Health Services | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228761015 |
| Principal investigator 1 | Exelixis Inc. | $1,000.00 | 02/13/2025 | Non-covered Recipient Entity Orange Coast Medical Center | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222383022 |
| Principal investigator 1 | Exelixis Inc. | $3,000.00 | 02/13/2025 | Non-covered Recipient Entity Orange Coast Medical Center | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222383024 |
| Principal investigator 1 | Exelixis Inc. | $1,200.00 | 02/13/2025 | Non-covered Recipient Entity Orange Coast Medical Center | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222383026 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $108,995.66 | 01/29/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185544633 |
| Principal investigator 1 | PFIZER INC. | $2,550.00 | 01/10/2025 | Non-covered Recipient Entity Memorial Health Services | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228801054 |